Xencor, Inc. (XNCR) Revenue History
Annual and quarterly revenue from 2014 to 2025
Compound Annual Growth Rate (CAGR)
Loading revenue history...
Revenue Growth Metrics
Revenue Breakdown (FY 2025)
XNCR's revenue distribution by segment and geography for fiscal year 2025
By Product/Segment
By Geography
XNCR Revenue Analysis (2014–2025)
As of March 1, 2026, Xencor, Inc. (XNCR) generated trailing twelve-month (TTM) revenue of $0, reflecting significant decline in growth of -239.0% year-over-year. The most recent quarter (Q4 2025) recorded $-97,339,000 in revenue, down 563.5% sequentially.
Looking at the longer-term picture, XNCR's historical revenue data shows various trends over time. The company achieved its highest annual revenue of $275.1 million in 2021.
Revenue diversification analysis shows XNCR's business is primarily driven by Royalty (64%), and Milestone (36%). With over half of revenue concentrated in Royalty, the company maintains significant focus in this area while developing other growth vectors.
When compared to Healthcare sector peers including REGN (+1.0% YoY), IMNM (-4.4% YoY), and CLDX (-78.6% YoY), XNCR has underperformed the peer group in terms of revenue growth. Compare XNCR vs REGN →
Peer Comparison
Compare XNCR's revenue metrics with industry peers
| Company | TTM Revenue | YoY Growth | 5Y CAGR | Op. Margin | Compare |
|---|---|---|---|---|---|
| XNCRCurrent | $0 | -239.0% | - | - | |
| REGN | $14.3B | +1.0% | +11.0% | 25.7% | |
| IMNM | $9M | -4.4% | - | -3382.4% | |
| CLDX | $2M | -78.6% | -27.4% | -19160.0% | |
| RXRX | $75M | +27.5% | +85.4% | -867.9% | |
| NRIX | $84M | +54.0% | +36.3% | -340.2% |
Historical Revenue Data
| Year | Revenue | YoY % | Gross Profit | Gross Margin | Op. Income | Op. Margin |
|---|---|---|---|---|---|---|
| 2025 | $0 | -100.0% | $0 | - | $0 | - |
| 2024 | $110.5M | -36.7% | $110.5M | 100.0% | $-178,408,000 | -161.5% |
| 2023 | $174.6M | +6.1% | $174.6M | 100.0% | $-132,362,000 | -75.8% |
| 2022 | $164.6M | -40.2% | $164.6M | 100.0% | $-82,473,000 | -50.1% |
| 2021 | $275.1M | +124.2% | $275.1M | 100.0% | $43.8M | 15.9% |
| 2020 | $122.7M | -21.7% | $-47,108,000 | -38.4% | $-76,797,000 | -62.6% |
| 2019 | $156.7M | +285.9% | $38.1M | 24.3% | $13.8M | 8.8% |
| 2018 | $40.6M | +13.7% | $-56,898,000 | -140.1% | $-79,370,000 | -195.5% |
| 2017 | $35.7M | -59.2% | $-36,061,000 | -101.0% | $-53,562,000 | -150.0% |
| 2016 | $87.5M | +215.3% | $35.6M | 40.7% | $22.5M | 25.8% |
See XNCR's True Return
Price is only half the story. See total return with reinvested dividends.
Launch CalculatorIs XNCR Undervalued?
See our Bear / Base / Bull DCF models and intrinsic value estimates.
View ValuationCompare XNCR vs AGIO
See how XNCR stacks up against sector leader Agios Pharmaceuticals, Inc..
Start ComparisonFrequently Asked Questions
Is XNCR's revenue growth accelerating or slowing?
XNCR revenue declined -239.0% year-over-year, contrasting with the 5-year CAGR of N/A. TTM revenue fell to $0.00. This reverses the prior growth trend.
What is XNCR's long-term revenue growth rate?
Xencor, Inc.'s 5-year revenue CAGR of N/A reflects the variable expansion pattern. Current YoY growth of -239.0% is below this long-term average.
How is XNCR's revenue distributed by segment?
XNCR reports revenue by product line and geographic region. Annual and quarterly breakdowns from 2014-2025 are available for download. Segment mix reveals concentration and diversification trends.